Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on Haemonetics, Lowers Price Target to $60

Morgan Stanley maintains Haemonetics (NYSE:HAE) with a Equal-Weight and lowers the price target from $68 to $60.

byBenzinga Newsdesk

January 7, 2022

1 minute read

Morgan Stanley maintains Haemonetics (NYSE:HAE) with a Equal-Weight and lowers the price target from $68 to $60.

Credit Suisse Downgrades Paysafe to Underperform

By Benzinga Newsdesk

Today, 4:39 AM

Credit Suisse analyst Timothy Chiodo downgrades Paysafe (NYSE:PSFE) from Neutral to Underperform.

PSFE

Valley National: Q4 Earnings Insights

By Benzinga Insights

Today, 4:39 AM

Valley National (NASDAQ:VLY) reported its Q4 earnings results on Thursday, January 27, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

VLY

Earnings Scheduled For January 11, 2022

By Benzinga Insights

Today, 4:39 AM

Companies Reporting Before The Bell • OrganiGram Holdings (NASDAQ:OGI) is projected to report quarterly loss at $0.02 per share on revenue of $23.95 million.

ACI

TeraWulf Highlights Commencement Of Mining Sustainable, Low-Cost Bitcoin

By Benzinga Newsdesk

Today, 4:39 AM

TeraWulf Inc. (NASDAQ:WULF) ("TeraWulf" or the "Company"), which was formed to own and operate fully integrated environmentally clean bitcoin mining facilities in the United States, today announced

WULF

Morgan Stanley Maintains Equal-Weight on Haemonetics, Lowers Price Target to $60

Related Posts

Credit Suisse Downgrades Paysafe to Underperform

Valley National: Q4 Earnings Insights

Earnings Scheduled For January 11, 2022

TeraWulf Highlights Commencement Of Mining Sustainable, Low-Cost Bitcoin